연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
1301. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Oh DY, Lee KW, Lee KH, Sohn CH, Park YS, Zang DY, Ryoo HM, Song HS, Kim JS, Kang HJ, Kim BS, Bang YJ.
Invest New Drugs. 2012 Jun;30(3):1164-74.
Link
1300. Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: a multicenter, cross-sectional study.
Oh DY, Crawford B, Kim SB, Chung HC, McDonald J, Lee SY, Ko SK, Ro J.
Asia Pac J Clin Oncol. 2012 Sep;8(3):282-91.
Link
1299. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.
Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, Lee HJ, Lee KW, Bang YJ.
Cancer. 2012 Dec 15;118(24):6162-70
Link
1298. Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy.
Kim JW, Cha Y, Kim SJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ.
Support Care Cancer. 2012 Feb;20(2):395-403.
Link
1297. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).
Kim SJ, Kim JW, Oh DY, Han SW, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ.
Am J Clin Oncol. 2012 Dec;35(6):549-56.
Link
1296. Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer.
Park J, Park E, Han SW, Im SA, Kim TY, Kim WH, Oh DY, Bang YJ.
Invest New Drugs. 2012 Aug;30(4):1404-12.
Link
1295. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
Nam HJ, Ching KA, Kan J, Kim HP, Han SW, Im SA, Kim TY, Christensen JG, Oh DY, Bang YJ.
Mol Cancer Ther. 2012 Feb;11(2):439-51.
Link
1294. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
Park E, Park J, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
Int J Oncol. 2012 Apr;40(4):1259-66
Link
1293. The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.
Nam HJ, Kim HP, Yoon YK, Song SH, Min AR, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
Invest New Drugs. 2012 Dec;30(6):2148-60.
Link
1292. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
Lim KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ.
Oncology. 2012;83(2):57-66.
Link